Avalo Therapeutics Inc (AVTX)
10.85
-0.64
(-5.57%)
USD |
NASDAQ |
May 10, 16:00
10.79
-0.06
(-0.55%)
After-Hours: 20:00
Avalo Therapeutics Research and Development Expense (Quarterly): 1.867M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.867M |
September 30, 2023 | 1.249M |
June 30, 2023 | 4.658M |
March 31, 2023 | 6.008M |
December 31, 2022 | 6.172M |
September 30, 2022 | 7.042M |
June 30, 2022 | 8.51M |
March 31, 2022 | 9.584M |
December 31, 2021 | 11.51M |
September 30, 2021 | 10.55M |
June 30, 2021 | 12.57M |
March 31, 2021 | 25.21M |
December 31, 2020 | 12.64M |
September 30, 2020 | 8.872M |
June 30, 2020 | 5.917M |
March 31, 2020 | 4.768M |
December 31, 2019 | 2.907M |
September 30, 2019 | 1.743M |
June 30, 2019 | 3.713M |
March 31, 2019 | 3.401M |
Date | Value |
---|---|
December 31, 2018 | 2.006M |
September 30, 2018 | 1.048M |
June 30, 2018 | 1.083M |
March 31, 2018 | 1.650M |
December 31, 2017 | 1.961M |
September 30, 2017 | 0.9646M |
June 30, 2017 | 0.4936M |
March 31, 2017 | 0.9531M |
December 31, 2016 | 0.7732M |
September 30, 2016 | 4.582M |
June 30, 2016 | 2.502M |
March 31, 2016 | 2.293M |
December 31, 2015 | 1.751M |
September 30, 2015 | 1.237M |
June 30, 2015 | 1.875M |
March 31, 2015 | 1.723M |
December 31, 2014 | 2.259M |
September 30, 2014 | 4.371M |
June 30, 2014 | 2.861M |
March 31, 2014 | 2.750M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.249M
Minimum
Sep 2023
25.21M
Maximum
Mar 2021
7.657M
Average
6.172M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
Imunon Inc | 3.553M |
iBio Inc | 1.535M |
Kodiak Sciences Inc | 46.63M |
Petros Pharmaceuticals Inc | 0.8343M |
Ocugen Inc | 9.504M |